SB 525334

Grouped product items
Size	Price	Qty
10mg	$135.00
50mg	$570.00

Catalog Number : 3562015

description

SB 525334 is a selective and potent inhibitor of the TGF-Beta receptor 1 (ALK5). It exhibits no inhibition of ALK2, ALK3, and ALK6. It blocks the activation of Smad2/3 by TGF-β1 in renal proximal tubule cells and attenuates bleomycin-induced pulmonary fibrosis.

Additional Information

Applications:	FA
Synonyms:	SB-525334, 6-(2-(tert-Butyl)-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline
Formulation:	Crystalline solid
Chemical Name:	6-[2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline
Molecular Formula:	C₂₁H₂₁N₅
Molecular Weight:	343.4
CAS Number	356559-20-1
Purity:	≥98%
Storage Conditions:	Product should be kept at -20°C.
References:	Higashiyama, H., Yoshimoto, D., Kaise, T., Matsubara, S., Fujiwara, M., Kikkawa, H., ... & Kinoshita, M. (2007). Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. Experimental and molecular pathology, 83(1), 39-46. Grygielko, E. T., Martin, W. M., Thornton, P., Tweed, C., & Laping, N. J. (2002, September). SB-525334, a novel TGF-beta type I receptor kinase inhibitor in the puromycin aminonucleoside model of renal disease. InJOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (Vol. 13, pp. 5A-5A). 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA: LIPPINCOTT WILLIAMS & WILKINS. Underwood, D. C., Osborn, R. R., Grygielko, E. T., & Laping, N. J. (2003). SB-525334, a novel TGF-beta type 1 receptor kinase inhibitor, prevents ans reverses Bleopmycin-induced pulmonary fibrosis in the rat.